At Thermo Fisher Scientific, we are powering the future of molecular testing and clinical trials.
Together, our global network and advanced next-generation sequencing (NGS) solutions are helping to advance both myeloid and lymphoid malignancy research.
Meet us at EHA 2024 to explore our comprehensive hemato-oncology portfolio and take a tour of the Ion Torrent Genexus System, the only automated NGS platform that can deliver results in as little as 24 hours.
Meet with our colleagues at PPD, part of Thermo Fisher Scientific, to learn more about participating in oncology clinical trials.
Profile a range of lymphoid mutations in a single test in as little as 24 hours and access a community network of leading researchers.
Advanced NGS solutions that can sequence multiple B- and T-cell receptor targets in a single reaction for highly sensitive and specific clone detection. Learn More
Absolute Q dPCR Liquid Biopsy Assays
Applied Biosystems Absolute Q Liquid Biopsy dPCR Assays offer a precise, cost-effective, and rapid method for monitoring response and resistance to treatment by testing for relevant cancer-driver and therapy-resistant mutations.
Hear Dr. Krigstein share his experience leveraging the Oncomine Myeloid Assay on the Genexus platform, highlighting the simple automated workflow, analytical validation performance data, and ability to obtain comprehensive molecular results in a single day.
Dr. Michael Krigstein
Consultant Haematologist
MBBS(Hons) FRACP FRCPA MCncrSc
SydPath, St Vincent's Hospital
Sydney, Australia
In an AMP workshop, Dr. Cecilia Yeung discussed the latest advances in the application of rapid NGS for myeloid genomic profiling. She shared analytical data from her lab using the Genexus System and provided an overview of exciting collaborations that are leveraging rapid NGS to advance research in hemato-oncology care.
Cecilia Yeung, MD
Associate Professor
Fred Hutchinson Cancer Center
Medical Director,
Fred Hutch CLIA laboratories
At EHA 2022, Dr. Dolors Colomer discussed the impact that the Oncomine Myeloid Assay GX had on turnaround times and laboratory efficiency. She presented compelling data on FLT3-ITD, showing 100% concordance between NGS and fragment analysis and the ability to detect low-frequency variants ranging in size from 12–180 bp.
Dolors Colomer, PhD
Head of Hematopathology
Hospital Clinic, IDIBAPS,
University of Barcelona, Spain
The Ion Torrent™ Genexus™ System is the only turnkey next-generation sequencing (NGS) solution that automates the end-to-end workflow from the biological specimen all the way to the final report and delivers results in as little as a single day.*
Thinking about how the Genexus System works and how it could fit into your lab?
In our virtual laboratory environment powered by augmented reality (AR) technology, you can see:
